Table 4.
KLB targeting drugs in clinical studies.
| Drug name | Design | Company | Clinical trials | Treatment | References |
|---|---|---|---|---|---|
| NGM282 | FGF19 analogue | NGM Biopharmaceuticals | NCT02135536 NCT05130047 | NASH, PBC, PSC | (121–123) |
| LY2405319 | FGF21 analogue | Lilly | ND | T2D | (124) |
| PF-05231023 | FGF21 analogue | Pfizer | ND | T2D | (31, 125) |
| BMS-986036 (Pegbelfermin) | PEGylated FGF21 analogue | Bristol-Myers Squibb | NCT03486899 NCT03486912 | NASH | (126–128) |
| AKR-001 (Efruxifermin) | Fc-FGF21 analogue | Akero Therapeutics | NCT04767529 NCT05039450 | T2D, NASH | (129, 130) |
| BFKB8488A (bFKB1) |
β-Klotho-dependent FGFR1c agonist | Genentech | NTC04171765 | NASH | (131) |
| MK-3655 (NGM313) | FGFR1c/β-Klotho complex agonist | Merck Sharp & Dohme | NTC04583423 | NASH | (132) |
NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; T2D, type 2 diabetes; ND, no data available.